Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA...

FDA Recall #D-0382-2026 — Class III — February 18, 2026

Recall #D-0382-2026 Date: February 18, 2026 Classification: Class III Status: Ongoing

Product Description

Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17

Reason for Recall

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Recalling Firm

Cipla USA, Inc. — Warren, NJ

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

164 cartons

Distribution

U.S.A. Nationwide

Code Information

Lot #: 5GJ0223, Exp 04/30/2027

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated